S
Steven P. Treon
Researcher at Harvard University
Publications - 536
Citations - 29713
Steven P. Treon is an academic researcher from Harvard University. The author has contributed to research in topics: Waldenstrom macroglobulinemia & Macroglobulinemia. The author has an hindex of 83, co-authored 506 publications receiving 25870 citations. Previous affiliations of Steven P. Treon include Brigham and Women's Hospital & Dana Corporation.
Papers
More filters
Journal ArticleDOI
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Steven P. Treon,Lian Xu,Guang Yang,Yangsheng Zhou,Xia Liu,Yang Cao,Patricia Sheehy,Robert Manning,Christopher J. Patterson,Christina K. Tripsas,Luca Arcaini,Geraldine S. Pinkus,Scott J. Rodig,Aliyah R. Sohani,Nancy L. Harris,Jason M. Laramie,Donald A Skifter,Stephen E Lincoln,Zachary R. Hunter +18 more
TL;DR: MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating WaldenStröm’s macrogalobulinesia and non-IgM LPL from B-cell disorders that have some of the same features.
Journal ArticleDOI
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith E. Davies,Noopur Raje,Noopur Raje,Noopur Raje,Teru Hideshima,Teru Hideshima,Teru Hideshima,Suzanne Lentzsch,Suzanne Lentzsch,Suzanne Lentzsch,Gloria Young,Gloria Young,Gloria Young,Yu-Tzu Tai,Yu-Tzu Tai,Yu-Tzu Tai,Boris Lin,Boris Lin,Boris Lin,Klaus Podar,Klaus Podar,Klaus Podar,Deepak K. Gupta,Deepak K. Gupta,Deepak K. Gupta,Dharminder Chauhan,Dharminder Chauhan,Dharminder Chauhan,Steven P. Treon,Steven P. Treon,Steven P. Treon,Paul G. Richardson,Paul G. Richardson,Paul G. Richardson,Robert L. Schlossman,Robert L. Schlossman,Robert L. Schlossman,Gareth J. Morgan,Gareth J. Morgan,Gareth J. Morgan,George W. Muller,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson,Kenneth C. Anderson +48 more
TL;DR: In vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function.
Journal ArticleDOI
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima,Dharminder Chauhan,Dharminder Chauhan,Yoshihito Shima,Yoshihito Shima,Noopur Raje,Noopur Raje,Faith E. Davies,Faith E. Davies,Yu-Tzu Tai,Yu-Tzu Tai,Steven P. Treon,Steven P. Treon,Boris Lin,Boris Lin,Robert L. Schlossman,Robert L. Schlossman,Paul G. Richardson,Paul G. Richardson,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson +24 more
TL;DR: Clinical activity of Thal against MM that is refractory to conventional therapy is demonstrated and mechanisms of anti-tumor activity of thalidomide and its potent analogs (immunomodulatory drugs [IMiDs]) are delineated.
Journal ArticleDOI
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Roger G. Owen,Steven P. Treon,Ayad Al-Katib,Rafael Fonseca,Philip R. Greipp,Mary L. McMaster,Enrica Morra,Gerassimos A. Pangalis,Jesús F. San Miguel,Andrew R. Branagan,Meletios A. Dimopoulos +10 more
TL;DR: This presentation represents consensus recommendations for the clinicopathological definition of Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002.
Journal ArticleDOI
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Steven P. Treon,Christina K. Tripsas,Kirsten Meid,Diane Warren,Gaurav Varma,Rebecca Green,Kimon V. Argyropoulos,Guang Yang,Yang Cao,Lian Xu,Christopher J. Patterson,Scott J. Rodig,James L. Zehnder,Jon C. Aster,Nancy L. Harris,Sandra Kanan,Irene M. Ghobrial,Jorge J. Castillo,Jacob P. Laubach,Zachary R. Hunter,Zeena Salman,Jianling Li,Mei Cheng,Fong Clow,Thorsten Graef,M. Lia Palomba,Ranjana H. Advani +26 more
TL;DR: Ibrutinib was highly active, associated with durable responses, and safe in pretreated patients with Waldenström's macroglobulinemia, and the effect of MYD88 and CXCR4 mutations on outcomes was investigated.